Last updated: 2026-10-13 23:19:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
MDxHealth SA (MDXH) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $0.66, with a market capitalisation of $56.27M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.40 to $5.33. This page covers its latest market performance, valuation, price trends and company information.
$56.27M | |
$0.60 | |
$131.70 | |
$0.40 | |
$0.60 | |
487.93K | |
5.76M | |
-- | |
$5.33 | |
$0.40 | |
-- | |
-- |
MDxHealth SA (MDXH) is trading at $0.65 in after-hours trading as of 2026-10-13 22:40:00, up 8.30% ($0.05) from the regular-session close of $0.60.
After-hours trading shows how investors are pricing MDXH after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, MDxHealth SA (MDXH) moved from $0.57 to $0.66, representing a gain of 15.06% ($0.09).
The stock traded between $0.56 and $0.67 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 160.91 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 5.2%
MDXH is currently trading at $0.66, placing it 5.2% of the way from its 52-week low of $0.40 to its 52-week high of $5.33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
| Employees | 364 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MDxHealth SA (MDXH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.